Urolithin A Mitophagy Priming for Exhaustion-Resistant T Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods are lacking for clinically-feasible induction of mitophagy to enhance T cell fitness in the tumor microenvironment for effective cancer therapy, particularly for microsatellite stable colorectal cancers, which are resistant to immune checkpoint blockade.
Innovation Solution
Utilizing urolithin A, a natural metabolite, as a mitophagy agonist to induce mitophagy in T cells, enhancing mitochondrial health and promoting T cell expansion and anti-tumor immunity through upregulation of MHC-I and expansion of T memory stem cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immune checkpoint blockade is used to treat colorectal cancer, then response rate is improved in microsatellite instable cancers, but treatment efficacy remains limited in microsatellite stable cancers which constitute the majority of cases
Solution Approach 1:
The invention changes the metabolic parameter of T cells by inducing mitophagy through urolithin A treatment, transforming the T cell metabolic state from exhausted to activated. This parameter change enables the therapy to work effectively across different cancer types, particularly microsatellite stable colorectal cancers that were previously resistant to immune checkpoint blockade alone.
Solution Approach 2:
The invention introduces mitophagy induction as an intermediary mechanism that bridges the gap between T cell adoption and effective anti-tumor response. By using urolithin A as a mediator to induce mitophagy in T cells before or during adoptive transfer, the therapy overcomes the limitation of T cell exhaustion in the tumor microenvironment and achieves broad efficacy.
2Reliability
If T cells are expanded and activated for adoptive therapy, then anti-tumor immunity is enhanced, but T cell exhaustion occurs in the tumor microenvironment limiting therapeutic efficacy
Solution Approach 1:
The invention performs preliminary mitophagy induction in T cells ex vivo before adoptive transfer to the tumor microenvironment. This preliminary action primes the T cells with enhanced mitochondrial function and metabolic fitness, enabling them to resist exhaustion and maintain functional persistence longer when confronted with the challenging tumor microenvironment.
Solution Approach 2:
The invention changes the metabolic parameter of T cells by inducing mitophagy, which transforms the T cell state from exhausted to activated with enhanced functional persistence. This parameter change in mitochondrial dynamics and metabolism enables T cells to sustain anti-tumor immunity for extended durations in the tumor microenvironment.
3Ease of manufacture
If conventional T cell therapy methods are used, then treatment protocol is simple, but mitochondrial dysfunction and T cell exhaustion limit therapeutic success
Solution Approach 1:
The invention introduces urolithin A as a simple intermediary compound that induces mitophagy in T cells. This small molecule mediator can be easily incorporated into existing T cell therapy protocols without complex procedural changes, yet it fundamentally improves mitochondrial function and therapeutic success rate by preventing T cell exhaustion.
Solution Approach 2:
The invention changes the metabolic parameter of T cells through mitophagy induction, transforming dysfunctional exhausted T cells into metabolically fit activated T cells. This parameter change in mitochondrial health is achieved through a simple additive approach that maintains protocol simplicity while dramatically improving therapeutic success.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Urolithin A induces mitophagy in T cells, improving their fitness and immune response, leading to enhanced anti-tumor immunity and therapeutic efficacy against various cancers, including colorectal cancer.
Implementation Method 1
Urolithin A (UA) is a natural metabolite of elagatinnines (ETs)... Concentrated forms of UA demonstrated that dietary supplementation induces mitophagy in vivo... Urolithin A induces MHC-I upregulation on tumor epithelia and promotes expansion of T memory stem cells (TSCM), thus strongly inducing a protective anti-tumor CD8+ T cell immunity.
Data Source
AI summary
The invention is based on the use of mitophagy agonists as defined in the claims, in particular Urolithin A, for improving mitochondrial health in immune cells such as T-cells. The invention provides new strategies to enhance immune cell based therapies, such as adoptive T-cell therapy. The compounds and compositions of the invention are preferably useful for therapies that involve in vitro T cell modification and expansion, such as modification of T cells with a chimeric antigen receptor (CAR) for treating an antigen associated disorder, such as cancer.